Head-To-Head Analysis: Amgen (AMGN) & BioSpecifics Technologies Corp (BSTC)
Amgen (NASDAQ: AMGN) and BioSpecifics Technologies Corp (NASDAQ:BSTC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitabiliy and valuation.
This table compares Amgen and BioSpecifics Technologies Corp’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioSpecifics Technologies Corp||43.43%||21.70%||18.71%|
Institutional and Insider Ownership
78.8% of Amgen shares are owned by institutional investors. Comparatively, 55.7% of BioSpecifics Technologies Corp shares are owned by institutional investors. 0.2% of Amgen shares are owned by insiders. Comparatively, 23.2% of BioSpecifics Technologies Corp shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of current ratings for Amgen and BioSpecifics Technologies Corp, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioSpecifics Technologies Corp||0||0||2||0||3.00|
Amgen currently has a consensus price target of $185.44, indicating a potential upside of 14.18%. BioSpecifics Technologies Corp has a consensus price target of $60.00, indicating a potential upside of 24.61%. Given BioSpecifics Technologies Corp’s stronger consensus rating and higher probable upside, analysts plainly believe BioSpecifics Technologies Corp is more favorable than Amgen.
Risk and Volatility
Amgen has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500. Comparatively, BioSpecifics Technologies Corp has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
Amgen pays an annual dividend of $4.60 per share and has a dividend yield of 2.8%. BioSpecifics Technologies Corp does not pay a dividend. Amgen pays out 43.7% of its earnings in the form of a dividend. BioSpecifics Technologies Corp has increased its dividend for 6 consecutive years.
Earnings & Valuation
This table compares Amgen and BioSpecifics Technologies Corp’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Amgen||$22.93 billion||5.21||$12.10 billion||$10.53||15.42|
|BioSpecifics Technologies Corp||$27.37 million||12.62||$18.61 million||$1.63||29.54|
Amgen has higher revenue and earnings than BioSpecifics Technologies Corp. Amgen is trading at a lower price-to-earnings ratio than BioSpecifics Technologies Corp, indicating that it is currently the more affordable of the two stocks.
BioSpecifics Technologies Corp beats Amgen on 10 of the 18 factors compared between the two stocks.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
About BioSpecifics Technologies Corp
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren’s contracture and Peyronie’s disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.